

Publications of the International Breast Cancer Study Group

Trial V

18. Ludwig Breast Cancer Study Group. Combination adjuvant chemotherapy for node-positive breast cancer. Inadequacy of a single perioperative cycle. *N Engl J Med* 319:677-683, 1988. (Trial V)
19. Ludwig Breast Cancer Study Group. On the safety of perioperative adjuvant chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil in breast cancer. *Eur J Cancer Clin Oncol* 24:1305-1308, 1988. (Trial V)
24. Ludwig Breast Cancer Study Group. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. *N Engl J Med* 320:491-496, 1989. (Trial V)
32. International (Ludwig) Breast Cancer Study Group: Prognostic importance of occult axillary lymph node metastases from breast cancers. *Lancet* 335:1565-1568, 1990. (Trial V)
38. Gelber RD, Goldhirsch A, Cavalli F: Quality-of-life adjusted evaluation of adjuvant therapies for operable breast cancer. *Ann Int Med* 114:621-628, 1991. (Trial V)
48. Gusterson BA, Gelber RD, Goldhirsch A., Price KN, Säve-Söderbergh J, Anbazhagan R, Styles K, Rudenstam C-M, Golouh R, Reed R, Martinez-Tello F, Tiltman A, Torhorst J, Grigolato P, Bettelheim R, Neville AM, Bürki K, Castiglione M, Collins J, Lindtner J, Senn HJ for the International Breast Cancer Study Group: Prognostic importance of c-erbB-2 expression in breast cancer. *J Clin Oncol* 10:1049-1056, 1992. (Trial V)
49. Spataro V, Price K, Goldhirsch A, Cavalli F, Simoncini E, Castiglione M, Rudenstam C-M, Collins J, Lindtner K, Gelber RD for the International Breast Cancer Study Group (formerly Ludwig Group): Sequential estrogen receptor determinations from primary breast cancer and at relapse: prognostic and therapeutic relevance. *Ann Oncol* 3:733-740, 1992. (Trials I-V)
52. Goldhirsch A, Castiglione M, Gelber RD for the International Breast Cancer Study Group: A single perioperative adjuvant chemotherapy course for node-negative breast cancer: five-year results of trial V. *J Natl Cancer Inst Monogr* 11:89-96, 1992. (Trial V)
54. Neville AM, Bettelheim R, Gelber R, Säve-Söderbergh J, Davis BW, Reed R, Torhorst J, Golouh R, Peterson HF, Price KN, Isley M, Rudenstam CM, Collins J, Castiglione M, Senn HJ, Goldhirsch A for the International Breast Cancer Study Group: Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. *J Clin Oncol* 10:696-705, 1992. (Trial V)
55. Gusterson BA, Taylor CW, Price KN, Gelber RD, Säve-Söderbergh J, Anbazhagan R, et al. Prognostic value of Helix Pomatia in breast cancer. *Br J Cancer* 68:146-150, 1993. (Trial V)
67. Goldhirsch A, Gelber R, Price K, Castiglione M, Coates A, Rudenstam C-M, Collins J, Lindtner J, Hacking A, Marini G, Byrne M, Schnürch G, Brunner K, Tattersall MHN, Forbes J, Senn H-J for the International Breast Cancer Study Group: Effect of systemic adjuvant treatment on first sites of breast cancer relapse. *Lancet* 343:377-381, 1994. (Trials I-V)
74. Crivellari D, Price KN, Hagen M, Goldhirsch A, Gelber RD, Castiglione M, Coates AS, Rudenstam CM, Collins J, Lindtner J, Cortés-Funes H, Gudgeon A, Simoncini E, Byrne M, Schnürch HG, Fey M, Tattersall MHN, Forbes JF, Cavalli F, Reed R, Senn H-J for the International (Ludwig) Breast Cancer Study Group (IBCSG): Routine tests during follow-up of patients after primary treatment for operable breast cancer. *Ann Oncol* 6:769-776, 1995. (Trials I-V)
75. Goldhirsch A, Gelber RD, Castiglione M, Price K, Rudenstam CM, Lindtner J, Collins J, Senn HJ, Cavalli F, Galligioni E, Fey M, Gudgeon A, Cortés-Funes H, Tattersall M, Marini G, Byrne M, Snyder R, Forbes JF, Kay R, Hürny C, Thürlimann B, Reed R, Gusterson B, Torhorst J, Säve-Söderbergh J, Coates A for the International Breast Cancer Study Group. The best available adjuvant treatments are within the framework of clinical trials. *Isr J Med Sci* 31:145-154, 1995. (Trials I-V)
86. Gusterson BA, Gelber RD, Goldhirsch A., Price KN, Säve-Söderbergh J, Anbazhagan R, Styles K, Rudenstam C-M, Golouh R, Reed R, Martinez-Tello F, Tiltman A, Torhorst J, Grigolato P, Bettelheim R, Neville AM, Bürki K, Castiglione M, Collins J, Lindtner J, Senn HJ for the International Breast Cancer Study Group: Prognostic importance of c-erbB-2 expression in breast cancer. *Classic Papers and Current Comments* 1:32-40, 1996. (Trial V)

89. Castiglione-Gertsch M, Tattersall M, Hacking A, Goldhirsch A, Gudgeon A, Gelber RD, Lindtner J, Coates A, Collins J, Isley M, Senn H-J, Rudenstam C-M for the IBCSG. Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy. *Eur J Cancer* 33:2321-2325, 1997. (Trials I-V)
90. Pestalozzi BC, Peterson HF, Gelber RD, Goldhirsch A, Gusterson BA, Lindtner J, Cortés-Funes H, Simoncini E, Byrne MJ, Golouh R, Rudenstam C-M, Castiglione-Gertsch M, Allegra CJ, Johnston PG. The prognostic importance of Thymidylate Synthase expression in early breast cancer. *J Clin Oncol* 15:1923-1931, 1997. (Trial V)
101. Colleoni M, Price K, Goldhirsch A, Castiglione-Gertsch M, Coates A, Lindtner J, Collins J, Gelber RD, Thürlimann B, Rudenstam CM, for the IBCSG. Dose-response effect of adjuvant Cyclophosphamide, Methotrexate, Fluorouracil (CMF) in node-positive breast cancer. *Eur J Cancer* 34:1693-1700, 1998. (Trials I-V)
103. Pinder SE, Murray S, Ellis IO, Trihia H, Elston CW, Gelber RD, Goldhirsch A, Lindtner J, Cortés-Funes H, Simoncini E, Byrne MJ, Golouh R, Rudenstam CM, Castiglione-Gertsch M, Gusterson BA. The importance of histological grade in invasive breast carcinoma and response to chemotherapy. *Cancer* 83:1529-1539, 1998. (Trial V)
105. Colleoni M, Price K, Castiglione-Gertsch M, Gelber R, Coates A, Goldhirsch A, for the International Breast Cancer Study Group (IBCSG). Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, fluorouracil (CMF regimen). *Lancet* 354:130-131, 1999. (Trials I-VII)
106. Cote RJ, Peterson HF, Chaiwun B, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Gusterson B, Neville AM. The role of the immunohistochemical detection of lymph node metastases in the management of breast cancer. *Lancet* 354:896-900, 1999. (Trial V)
108. Colleoni M, O'Neill A, Goldhirsch A, Gelber RD, Bonetti M, Thürlimann B, Price KN, Castiglione-Gertsch M, Coates AS, Lindtner J, Collins J, Senn H-J, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortés-Funes H, Veronesi A, Fey M, Rudenstam C-M, for the International (Ludwig) Breast Cancer Study Group. Identifying breast cancer patients at high risk for bone metastases. *J Clin Oncol*, 18: 3925-3935, 2000. (Trials I-VII)
112. Aebi S, Gelber S, Castiglione-Gertsch M, Gelber RD, Collins J, Thürlimann B, Rudenstam CM, Lindtner J, Crivellari D, Cortés-Funes H, Simoncini E, Werner ID, Coates AS, Goldhirsch A, for the International Breast Cancer Study Group (IBCSG). Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? *Lancet*, 355: 1869-1874, 2000. (Trials I-VI)
115. Colleoni M, Bonetti M, Coates AS, Castiglione-Gertsch M, Gelber RD, Price K, Rudenstam C, Lindtner J, Collins J, Thürlimann B, Holmberg S, Veronesi A, Marini G, Goldhirsch A, for the International Breast Cancer Study Group. Early start of adjuvant chemotherapy improves treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptor. *J Clin Oncol* 18: 584-590, 2000. (Trials I-V)
118. Colleoni M, Gelber S, Coates A, Castiglione-Gertsch M, Gelber RD, Price K, Rudenstam CM, Lindtner J, Collins J, Thürlimann B, Holmberg S, Cortés-Funes H, Simoncini E, Murray E, Fey M, Goldhirsch A, for the IBCSG. Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer. *J Clin Oncol* 19: 4141-4149, 2001. (Trial V)
119. Goldhirsch A, Gelber RD, Yothers G, Gray, RJ, Green S, Bryant J, Gelber S, Castiglione-Gertsch M, Coates AS. Adjuvant therapy for very young women with breast cancer: need for tailored treatments. *J Natl Cancer Inst Monogr*, No. 30:44-51, 2001. (Trials I-VI)
122. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Säve-Söderbergh J, Anbazhagan R, Styles K, Rudenstam C-M, Golouh R, Reed R, Martinez-Tello F, Tiltman A, Torhorst J, Grigolato P, Bettelheim R, Neville AM, Bürki K, Castiglione M, Collins J, Lindtner J, Senn HJ, for the International Breast Cancer Study Group: Prognostic importance of c-erbB-2 expression in breast cancer. *J Clin Oncol/Classic Papers and Current Comments* 5:908-916, 2001. (Trial V)
125. Gelber S, Coates AS, Goldhirsch A, Castiglione-Gertsch M, Marini G, Lindtner J, Edelmann DZ, Gudgeon A, Harvey V, Gelber RD, for the International Breast Cancer Study Group (IBCSG). Effect of pregnancy on overall survival following the diagnosis of early stage breast cancer. *J Clin Oncol*, 19:1671-1675, 2001. (Trials V and VI)
126. Kitchen PRB, Smith HJ, Henderson MA, Goldhirsch A, Castiglione-Gertsch M, Coates AS, Gusterson B, Brown RW, Gelber RD, Collins JP. Tubular carcinoma of the breast: Prognosis and response to adjuvant systemic therapy. *ANZ J Surg* 71:27-31, 2001. (Trials I-14)

131. Trihia H, Murray S, Price K, Gelber RD, Golouh R, Goldhirsch A, Coates AS, Collins J, Castiglione-Gertsch M, Gusterson BA. Ki-67 expression in breast carcinoma: Its association with grading systems, clinical parameters, and other prognostic factors - A surrogate marker? *Cancer* 97:1321-1331, 2003. (Trial V)
133. Spataro VJ, Litman H, Viale G, Maffini F, Masullo M, Golouh R, Martinez-Tello FJ, Grigolato P, Shilkin KB, Gusterson BA, Castiglione-Gertsch M, Price K, Lindtner J, Cortés-Funes H, Simoncini E, Byrne MJ, Collins J, Gelber RD, Coates AS, Goldhirsch A. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: Results from International Breast Cancer Study Group Trial V. *Cancer* 97:1591-1600, 2003. (Trial V)
134. Wallgren A, Bonetti M, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Holmberg SB, Lindtner J, Thürlimann B, Fey M, Werner ID, Forbes JF, Price K, Coates AS, and Collins J for the IBCSG. Risk factors for locoregional recurrence among breast cancer patients: Results from International Breast Cancer Study Group Trials I Through VII. *J Clin Oncol* 21:1205-1213, 2003. (Trials I-VII)
145. Berclaz G, Li S, Price KN, Coates AS, Castiglione-Gertsch M, Rudenstam C-M, Holmberg SB, Lindtner J, Eržen D, Collins J, Snyder R, Thürlimann B, Fey MF, Mendiola C, Werner ID, Simoncini E, Crivellari D, Gelber RD, Goldhirsch A, on behalf of the IBCSG. Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. *Ann Oncol* 15: 875-884, 2004. (Trials I-VII)
151. Colleoni M, Zahrieh D, Gelber RD, Holmberg SB, Mattsson JE, Rudenstam C-M, Lindtner J, Eržen D, Snyder R, Collins J, Fey MF, Thürlimann B, Crivellari D, Murray E, Mendiola C, Pagani O, Castiglione-Gertsch M, Coates AS, Price K, Goldhirsch A. Site of primary tumor has a prognostic role in operable breast cancer: the International Breast Cancer Study Group experience. *J Clin Oncol* 23:1390-1400, 2005. (Trials I-VII, IX) (Journal impact factor 9.8)
158. Colleoni M, Li S, Gelber RD, Price KN, Coates AS, Castiglione-Gertsch M, Goldhirsch A for the International Breast Cancer Study Group. Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index. *Lancet* 366:1108-1110, 2005. (Trials I, II, V, VI) (Journal impact factor 21.7)
169. Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindtner J, Collins J, Crivellari D, Fey MF, Murray E, Pagani O, Simoncini E, Castiglione-Gertsch M, Gelber RD, Coates AS, Goldhirsch A for the IBCSG. Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). *Ann Oncol* 17:935-944, 2006. (Trials I-IX) (Journal impact factor 4.3).
184. Karlsson P, Cole BF, Price, KN, Coates AS, Castiglione-Gertsch M, Gusterson BA, Murray E, Lindtner J, Collins JP, Holmberg SB, Fey MF, Thürlimann B, Crivellari D, Forbes JF, Gelber RD, Goldhirsch A, Wallgren A. The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer. *J Clin Oncol* 25:2019-2026, 2007. (Trials I-IX) (Journal impact factor 11.8)
190. Partridge A, Gelber S, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Winer E. Age of menopause among women who remain premenopausal following treatment for early breast cancer: Long-term results from International Breast Cancer Study Group Trials V and VI, *Eur J Cancer* 43:1646-1653, 2007. (Trials V and VI) (Journal impact factor 3.7)
209. Pestalozzi BC, Zahrieh D, Mallon E, Gusterson BA, Price KN, Gelber RD, Holmberg SB, Lindtner J, Snyder R, Thürlimann B, Murray E, Viale G, Castiglione-Gertsch M, Coates AS, Goldhirsch A. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. *J Clin Oncol* 26:3006-3014, 2008. (Trials I-15) (Journal impact factor 13.6).